Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

The unleashing of antitumor T cell responses has ushered in a new era of cancer treatment. Although these therapies can cause dramatic tumor regressions in some patients, many patients inexplicably see no benefit. Mice have been used in two studies to investigate what might be happening. 
 
 Researchers in the journal Science find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade.
 
Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis–specific T cells.
 
Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties.
 
This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.
 
http://www.sciencemag.org/content/350/6264/1079.abstract
 
 
Edited

Rating

Unrated
Rating: